SynthesisBioscience reports2019
Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis.
Synthesis in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis.Cardiology journal · 2025Pooled it
- Diagnostic and prognostic value of circulating biomarkers in heart failure.Frontiers in cardiovascular medicine · 2025Pooled it
- Prognostic Value of Cystatin C Across Ejection Fraction Spectrum in Heart Failure With Normal to Mild Renal Dysfunction Original Investigation.Clinical cardiology · 2026Article
- Predictive performance of blood urea nitrogen, cystatin C, and their ratio for in-hospital mortality in sepsis: a Chinese two-center analysis.Open medicine (Warsaw, Poland) · 2026Article
- Association of Osteopontin and selective glomerular hypofiltration syndrome with hospitalization for kidney failure in acute heart failure patients.BMC nephrology · 2025Article
- Cystatin C as a predictor of renal recovery and in hospital mortality in patients with acute kidney injury and liver cirrhosis.BMC nephrology · 2025Article
- [High serum cystatin C is an independent risk factor for poor renal prognosis in IgA nephropathy].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Beyond linearity: a threshold effect links serum creatinine to SIRI in osteoporotic fractures.Frontiers in medicine · 2025Article
- Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach.International journal of molecular sciences · 2024Review
- The predictive value of the triglyceride glucose index combined with cystatin C for the prognosis of patients with acute coronary syndrome.Frontiers in endocrinology · 2024Article
- Heart Failure: Is There an Ideal Biomarker?Reviews in cardiovascular medicine · 2023Review
- Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: a narrative review.Biochemia medica · 2023Review
- Impact of cystatin C-derived glomerular filtration rate in patients undergoing transcatheter aortic valve implantation.Frontiers in cardiovascular medicine · 2023Article
- Article
- Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure.Journal of personalized medicine · 2022Review
- The value of cystatin C in evaluating the severity and prognosis of patients with severe fever with thrombocytopenia syndrome.BMC infectious diseases · 2022Article
- Integrative analyses of biomarkers and pathways for heart failure.BMC medical genomics · 2022Article
- Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study.Journal of the American Heart Association · 2022Article
- Non-linear association of cystatin C and all-cause mortality of heart failure: A secondary analysis based on a published database.Frontiers in cardiovascular medicine · 2022Article
- Improving the prediction of long-term readmission and mortality using a novel biomarker panel.Journal of cardiac surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating cystatin C (cys-C/CYC) has been identified as an independent predictor of all-cause mortality in patients with coronary artery disease and the general population. This meta-analysis aimed to systematically evaluate the association between elevated cys-C level and all-cause mortality and rehospitalization risk amongst patients with heart failure (HF). PubMed and Embase databases were searched until December 2017. All prospective observational studies that reported a multivariate-adjusted risk estimate of all-cause mortality and/or rehospitalization for the highest compared with lowest cys-C level in HF patients were included. Ten prospective studies involving 3155 HF patients were included. Meta-analysis indicated that the highest compared with lowest cys-C level was associated with an increased risk of all-cause mortality (hazard ratio (HR): 2.33; 95% confidence intervals (CI): 1.67-3.27;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.